Alpha1-antitrypsin replacement therapy controls fibromyalgia symptoms in 2 patients with PI ZZ alpha1-antitrypsin deficiency.
Two Spanish sisters with alpha1-antitrypsin (AAT) deficiency and fibromyalgia (FM) started AAT replacement therapy with commercial alpha1-antitrypsin infusions in 1992. They both experienced a rapid, progressive, and constant control of their FM symptoms during the next 6 years (1992-98). However, in 1998, treatment of both patients was affected by the worldwide commercial shortage of AAT replacement therapy; replacement therapy infusions were halted for about 4-6 consecutive months every year for 5 years. As a result, we observed a striking recurrence of FM symptoms. Equally striking was the total disappearance of these symptoms when AAT replacement therapy infusions were resumed.
Department of Internal Medicine, Respiratory Diseases Branch, Hospital Valle del Nalón, Asturias, Spain. ignacio.blanco@sespa.princast.es
Ignacio
I
Blanco
Hortensia
H
Canto
Frederick Joseph
FJ
de Serres
Enrique
E
Fernandez-Bustillo
Maria Carmen
MC
Rodríguez
D000328:Adult; D005260:Female; D005356:Fibromyalgia / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010375:Pedigree; D035781:Siblings; D000515:alpha 1-Antitrypsin / Q000627:therapeutic use*; D019896:alpha 1-Antitrypsin Deficiency / Q000150:complications / Q000188:drug therapy* / Q000235:genetics*
D000515:alpha 1-Antitrypsin